-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640

Benzinga·11/03/2026 16:14:15
Listen to the news
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.